Meril Lifesciences introduces MISSO, a revolutionary surgical robotics system for knee replacements that not only slashes costs by 66% but also promises to reshape the healthcare industry. Crafted entirely in India, this innovative system, with its AI-enhanced pre-operative planning efficiency of 83%, is set to redefine the standards of surgical precision and patient care.
Meril Lifesciences, a medicine technology company, launches MISSO, a surgical robotics system for knee replacements. By designing, engineering, and manufacturing in India, MISSO achieves a 66% cost reduction. Its compact design is ideal for smaller hospital operating rooms in Tier II and III cities. Its AI integration reduces pre-operative planning time by 83%, creating personalized plans based on the patient’s bone structure.
With a strategic plan to deploy over 1,000 units in the next three years, starting with 200 units manufactured at its Vapi facility in the first year, Meril Lifesciences is poised for significant growth. The orthopaedic segment, currently a Rs 1,000 crore business for Meril, is projected to reach Rs 1,500 crore. This expansion into the medical vertical, which sees a turnover of around Rs 3,500 crore annually, underscores Meril’s commitment to innovation and market leadership.
In addition to knee replacements, Meril is developing applications for hip, shoulder, and ankle replacements and advancements in arthroscopy, spinal surgery, and trauma surgeries through software enhancements.
Manish Deshmukh, head of marketing at Meril, emphasizes that the launch of the MISSO knee replacement robot is a testament to the collective efforts of the company and its stakeholders. With MISSO, India aims for self-reliance in robotic surgery, a goal that is only achievable with the support and collaboration of medical professionals, hospital administrators, investors, and individuals interested in advancements in medical technology.
Meril Lifesciences is on a mission to democratize robotic surgery in India. By significantly reducing equipment costs, from Rs 3.35 lakh in smaller hospitals to Rs 5.5-6 lakh in larger ones, Meril aims to make robotic surgery more accessible, particularly in Tier II and III cities. This commitment to affordability and accessibility is a testament to Meril’s dedication to improving healthcare for all.
Meril, a part of the Bilakhia Group headquartered in Gujarat, is known for its commitment to quality and innovation. Following regulatory approvals, Meril intends to export its advanced MISSO knee replacement robot to US and European markets, a move that underscores the company’s confidence in the product’s performance and safety. This expansion into international markets is a testament to Meril’s dedication to leveraging its medical technology and innovation expertise to address global healthcare needs.
